Preferences help
enabled [disable] Abstract
Number of results
2019 | 2 | 1 | 70-77
Article title

Cardiovascular and metabolic side effects of second-generation antipsychotics – narrative review

Title variants
Languages of publication
Since their introduction, the use of second generation antipsychotics (SGAs) has extended far beyond schizophrenia. With the increased usage of these agents, particular attention has been paid to their metabolic and cardiac side effects. This narrative review is an attempt to briefly summarize the conclusions from recently published systematic reviews on cardio-metabolic side effects of SGAs. Although no SGA is entirely free of these adverse effects, there are major differences in their prevalence between the specific medications. Numerous studies demonstrated particularly unfavorable side effect profiles of olanzapine and clozapine. The lack of conclusive data is a major limitation for many studies, particularly in the pediatric population. In this article we also discussed the meanings of these findings, suggested cardio-metabolic screening during SGA treatment and side effect management strategies.
Physical description
  • Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4–10. doi:10.1111/j.1600-0447.2009.01425.x.
  • Waszak PM, Zagozdzon P, Pierucka M, Kubanek A. Antipsychotic Medication Prescribing Trends in a Pediatric Population in Northern Poland 2008-2012. J Child Adolesc Psychopharmacol 2018;28:631–6. doi:10.1089/cap.2017.0154.
  • Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017;Volume 13:757–77. doi:10.2147/TCRM.S117321.
  • De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114–26. doi:10.1038/nrendo.2011.156.
  • Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophr Res 2017;190:18–27. doi:10.1016/j.schres.2017.03.031.
  • Bak M, Fransen A, Janssen J, Os J Van, Drukker M. Almost All Antipsychotics Result in Weight Gain : A Meta- Analysis 2014;9:10–2. doi:10.1371/journal.pone.0094112.
  • Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: A systematic review and implications for treatment. Front Neurosci 2018;11. doi:10.3389/fnins.2017.00741.
  • Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339–47. doi:10.1002/wps.20252.
  • Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf 2017;40:771–81. doi:10.1007/s40264-017-0543-0.
  • Pillay J, Boylan K, Newton A, Hartling L, Vandermeer B, Nuspl M, et al. Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update. Can J Psychiatry 2018:1–18. doi:10.1177/0706743718779950.
  • Jensen KG jessing, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK atrine. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 2015;54:25–36. doi:10.1016/j.jaac.2014.10.002.
  • Bobo W V., Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013;70:1067–75. doi:10.1001/jamapsychiatry.2013.2053.
  • Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: A comprehensive review. CNS Drugs 2014;28:887–920. doi:10.1007/s40263-014-0196-9.
  • Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Can J Psychiatry 2015;60:215–22. doi:10.1177/070674371506000503.
  • Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: A meta-analysis of thirteen cohort studies. J Psychiatr Res 2013;47:1549–56. doi:10.1016/j.jpsychires.2013.07.011.
  • Hsu W-T, Esmaily-Fard A, Lai C-C, Zala D, Lee S-H, Chang S-S, et al. Antipsychotics and the Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis of Observational Studies. J Am Med Dir Assoc 2017;18:in press. doi:10.1016/j.jamda.2017.02.020.
  • Yu Z -h., Jiang H-Y, Shao L, Zhou Y -y., Shi H -y., Ruan B. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol 2016:624–32. doi:10.1111/bcp.12985.
  • Ljungdalh PM. Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature review. Eur J Psychiatry 2017;31:172–86. doi:10.1016/j.ejpsy.2017.08.001.
  • John A, Mcgregor J, Jones I, Chim S, Walters JTR, Owen MJ, et al. Premature mortality among people with severe mental illness - New evidence from linked primary care data. Schizophr Res 2018;199:154–62. doi:10.1016/j.schres.2018.04.009.
  • Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: A Swedish national cohort study. JAMA Psychiatry 2013;70:931–9. doi:10.1001/jamapsychiatry.2013.1394.
  • Gal G, Munitz H, Levav I. Health care disparities among persons with comorbid schizophrenia and cardiovascular disease: A case-control epidemiological study. Epidemiol Psychiatr Sci 2016;25:541–7. doi:10.1017/S2045796015000852.
  • Perry BI, McIntosh G, Weich S, Singh S, Rees K. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. The Lancet Psychiatry 2016;3:1049–58. doi:10.1016/S2215-0366(16)30262-0.
  • Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 2017:bjp.bp.117.200907. doi:10.1192/bjp.bp.117.200907.
  • Chacón F, Mora F, Gervás-Ríos A, Gilaberte I. Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry 2011;10:1–10. doi:10.1186/1744-859X-10-22.
  • Stroup T, McEvoy J. Comparison of antipsychotics for metabolic problems (CAMP): a randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or. Am J … 2011;168:947–56. doi:10.1176/appi.ajp.2011.10111609.
  • Rummel-Kluge C, Komossa K. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr … 2010;123:225–233. doi:10.1016/j.schres.2010.07.012.
  • Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231–41. doi:10.2147/NDT.S113099.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.